We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

By LabMedica International staff writers
Posted on 15 Nov 2023
Print article
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies and antigens used by IVD manufacturers.  With the acquisition of 100% of the shares of ViroStat, Medix Biochemica can offer market-leading infectious disease antibodies and antigens to its customers for developing IVD immunoassay tests.

ViroStat is a primary manufacturer of antibodies and antigens used for the detection of respiratory agents, STD agents, gastrointestinal agents/toxins, and food-borne pathogens. The company is widely recognized for its high-affinity antibodies to Influenza A, Influenza B, RSV, and Strep A for use in rapid lateral flow devices. The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials, brings complementary scientific capabilities, and further strengthens its local presence in the USA.  The acquisition is in line with Medix Biochemica’s strategic vision of achieving the status of first-choice partner for the global IVD industry and positions it as a leading supplier of critical raw materials to fight infectious diseases.   

“We are very excited to welcome the whole ViroStat team to Medix Biochemica,” said Steve Ferguson, CEO of Medix Biochemica. “The partnership with ViroStat provides Medix Biochemica with market-leading products for a broad range of infectious diseases as well as further strengthens our scientific capabilities and network in this largest diagnostic area of IVD antibodies and antigens. There has been a long-standing business relationship between ViroStat and Medix Biochemica, and we have great respect for what Doug, Duncan, and the whole ViroStat team have built over the last 38 years. I am highly excited about the portfolio and cultural fit between our teams and looking forward to jointly growing our business to enable our customers to combat infectious diseases globally”. 

“Partnering with Medix Biochemica represents an exciting synergy of complementary product portfolios,” added Douglas McAllister, President of ViroStat who founded the company in 1985. “ViroStat brings validated antibody pairs especially for rapid test IVDs at a time when worldwide demand for self-testing is poised for rapid growth while our R&D activity endeavors to stay ahead of new and emerging pathogens. We are very pleased and excited to be joining the Medix Biochemica family. This is a great fit.”

Related Links:
Medix Biochemica
ViroStat LLC

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Automatic Nucleic Acid Extractor
GeneRotex 24

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.